Your browser doesn't support javascript.
loading
Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.
Abolhassani, Nazanin; Castioni, Julien; Marques-Vidal, Pedro; Vollenweider, Peter; Waeber, Gérard.
Afiliação
  • Abolhassani N; Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
  • Castioni J; Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
  • Marques-Vidal P; Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland. Pedro-Manuel.Marques-Vidal@chuv.ch.
  • Vollenweider P; Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
  • Waeber G; Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Eur J Clin Pharmacol ; 73(9): 1187-1194, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28634642
ABSTRACT

OBJECTIVES:

This study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample.

METHODS:

Baseline (2003-2006) and follow-up (2009-2012) data are from 4679 participants aged between 35 and 75 years (53.5% women, mean age 52.6 ± 10.6 years) from the population of Lausanne, Switzerland. Polypharmacy was defined by the regular use of ≥5 drugs. Four categories of change were defined never (no polypharmacy at baseline and follow-up), initiating (no polypharmacy at baseline but at follow-up), maintaining, or quitting.

RESULTS:

Polypharmacy increased from 7.7% at baseline to 15.3% at follow-up. Cardiovascular drugs were the most prescribed medicines at baseline and follow-up. Gender, age, obesity, smoking, previously diagnosed hypertension, or diabetes or dyslipidemia were significantly and independently associated with initiating and maintaining polypharmacy.

CONCLUSION:

In a population-based sample, prevalence of polypharmacy doubled over a 5.6-year period. The main determinants of initiating polypharmacy were age, overweight and obesity, smoking status, and previously diagnosed cardiovascular risk factors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimedicação Tipo de estudo: Etiology_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimedicação Tipo de estudo: Etiology_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article